Touyun Biotech Group (HKSE:01332) Debt-to-EBITDA : -2.27 (As of Jun. 2023)

View and export this data going back to 2000. Start your Free Trial

What is Touyun Biotech Group Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Touyun Biotech Group's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was HK$154.9 Mil. Touyun Biotech Group's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was HK$212.7 Mil. Touyun Biotech Group's annualized EBITDA for the quarter that ended in Jun. 2023 was HK$-161.8 Mil. Touyun Biotech Group's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2023 was -2.27.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Touyun Biotech Group's Debt-to-EBITDA or its related term are showing as below:

HKSE:01332' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -3.84 Med: -1.59 Max: 0.77
Current: -1.45

During the past 13 years, the highest Debt-to-EBITDA Ratio of Touyun Biotech Group was 0.77. The lowest was -3.84. And the median was -1.59.

HKSE:01332's Debt-to-EBITDA is ranked worse than
100% of 326 companies
in the Packaging & Containers industry
Industry Median: 2.525 vs HKSE:01332: -1.45

Touyun Biotech Group Debt-to-EBITDA Historical Data

The historical data trend for Touyun Biotech Group's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Touyun Biotech Group Debt-to-EBITDA Chart

Touyun Biotech Group Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-EBITDA

Get a 7-Day Free Trial

-1.90

-1.99

-3.84

-2.74

-1.45

Touyun Biotech Group Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-EBITDA	Get a 7-Day Free Trial															-3.74	-2.77	-1.77	-2.27	-1.05

Competitive Comparison of Touyun Biotech Group's Debt-to-EBITDA

For the Packaging & Containers subindustry, Touyun Biotech Group's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Touyun Biotech Group's Debt-to-EBITDA Distribution in the Packaging & Containers Industry

For the Packaging & Containers industry and Consumer Cyclical sector, Touyun Biotech Group's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Touyun Biotech Group's Debt-to-EBITDA falls into.

Touyun Biotech Group Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Touyun Biotech Group's Debt-to-EBITDA for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(200.822	+	194.192)	/	-144.393
	=	-2.74

Touyun Biotech Group's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(154.878	+	212.73)	/	-161.838
	=	-2.27

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Jun. 2023) EBITDA data.

Touyun Biotech Group (HKSE:01332) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Touyun Biotech Group Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Touyun Biotech Group's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Touyun Biotech Group (HKSE:01332) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Consumer Cyclical » Packaging & Containers » Touyun Biotech Group Ltd (HKSE:01332) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

6 Tonnochy Road, 12th Floor, Kwan Chart Tower, Wanchai, Hong Kong, HKG

Website

https://www.touyunbiotech.com.hk

Touyun Biotech Group Ltd, formerly China Touyun Tech Group Ltd, an investment holding company, designs, develops, manufactures, and sells packaging products and point-of-sales display units. It operates with four business segments, Packaging Products, Treasury Investment, QR code business, and Chlamydomonas reinhardtii product business. Through the Packaging Products segment, it offers watch boxes, jewelry boxes, eyewear cases, bags and pouches, and display units whereas the Treasury segment engages in the trading of securities and money lending activities. It derives a majority of its revenue from the Packaging products. The business activity of the group is operated in Hong Kong, Mainland China, North and South America, and other countries.

Touyun Biotech Group (HKSE:01332) Headlines

No Headlines